Research
Hormonal
Adipokine-based therapies face major biological roadblocks including lack of efficacy in humans despite rodent success, incomplete understanding of mechanisms, and adverse side effects.
Developing new obesity drugs based on adipokines is difficult because success in mice often fails in humans, mechanisms are often unknown, and side effects are common. This makes the drug development process long, expensive, and prone to failure.
StrongQualifiesHIGH confidence
Additional road blocks include: (1) that a mechanistic concept derived from rodent studies does not translate into effective treatment in humans, (2) lack of human data, (3) an incomplete understanding of the mechanism of action, (4) adverse drug and side effects...
Why this rating
Based on the author's comprehensive review of multiple adipokine candidates and clinical trial outcomes.
Source
Adipokines – removing road blocks to obesity and diabetes therapy
Matthias Blüher · Molecular Metabolism · 2014
DOI 10.1016/j.molmet.2014.01.005
narrative_reviewCited 269×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Exogenous leptin administration fails to produce significant weight loss in individuals with common obesity due to central leptin resistance, despite being effective in treating congenital leptin deficiency.Good
- Combining leptin analogs (metreleptin) with amylin analogs (pramlintide) can restore leptin sensitivity and produce significant weight loss in obesity, overcoming the resistance seen with leptin monotherapy.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →